LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?